DDR1 and cancer: As reported, the DDR1 extracellular domain contributes significantly to immune exclusion, providing great obstacles for immune cells’ infiltration into cancer tissue; thus, targeting DDR1 via monoclonal antibody could reverse this situation and provide a strategy for tumor treatment [132,133].